Table 4.
The cross-lagged path analysis for the temporal association between hyperuricemia and MAFLD.
| β1(hyperuricemia to subsequent MAFLD) | P-value | β2(MAFLD to subsequent hyperuricemia) | P-value | RMR | CFI | |
|---|---|---|---|---|---|---|
| Crude | 0.058 (0.046, 0.071) | <0.001 | 0.028 (0.016, 0.040) | <0.001 | 0.018 | 0.992 |
| Model 1 | 0.040 (0.028, 0.051) | <0.001 | 0.027 (0.013, 0.040) | <0.001 | 0.020 | 0.990 |
| Model 2 | 0.039 (0.027, 0.051) | <0.001 | 0.032 (0.019, 0.045) | <0.001 | 0.021 | 0.988 |
| Model 3 | 0.039 (0.026, 0.051) | <0.001 | 0.030 (0.017, 0.043) | <0.001 | 0.022 | 0.988 |
MAFLD, metabolic dysfunction-associated fatty liver disease; RMR, root mean square residual; CFI, comparative fitness index.
Model 1: adjusted for age, sex.
Model 2: adjusted for age, sex, low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), alanine aminotransferase (ALT), blood urea nitrogen (BUN), systolic blood pressure (SBP), triglycerides (TG).
Model 3: adjusted for age, sex, low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), alanine aminotransferase (ALT), blood urea nitrogen (BUN), systolic blood pressure (SBP), triglycerides (TG), insulin resistance.